Under the terms of the transaction, CoLucid shareholders will receive only $46.50 in cash for each share of CoLucid stock they own. The investigation concerns whether the Board of CoLucid breached their fiduciary duties to shareholders and whether Eli Lilly is underpaying for the Company. The transaction may undervalue the Company and may not be in the CoLucid shareholders best interests. For example, the price being paid by Eli Lilly is below both an analyst price target of $52.00 per share and below the premium paid in comparable transactions.
If you own shares of CoLucid stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 510, Bala Cynwyd, PA 19004, by visiting http://www.brodskysmith.com/cases/colucid-pharmaceuticals-inc-nasdaq-clcd/, or calling toll free 877-LEGAL-90.
Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert--brodsky--smith-llc-announces-an-investigation--of--the-board-of-directors-of-colucid-pharmaceuticals-inc--clcd-300394288.html
SOURCE Brodsky & Smith, LLC